GSK’s Jemperli In Search Of Lung Cancer Foothold And TIM-3 Combo Could Be Best Chance
Keytruda Head-To-Head Is Ambitious
The company wants to break into non-small cell lung cancer therapy but is unlikely to score a true hit in its head-to-head with Merck & Co’s blockbuster Keytruda.
You may also be interested in...
GSK is abandoning one of its new drug prospects after it failed in hard-to-treat rheumatoid arthritis patients at Phase III, raising the stakes for more key readouts due shortly.
Roche’s global head of neurodegeneration, Rachelle Doody, talks to Scrip about the failure of gantenerumab and its next-generation ‘brain shuttle’ technology for Alzheimer’s disease.
Several big pharma companies may be interested in buying Mirati, but could baulk at paying up to $12bn for its as-yet-unproven oncology portfolio.